The seminoma-associated paraneoplastic syndrome market — addressing a rare neurological disorder in which the immune system's response to a testicular seminoma mistakenly attacks the brain and nervous system — is gaining genuine traction as diagnostic technology improves and clinicians increasingly recognize this condition as a critical, sometimes life-saving diagnostic clue rather...